Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00275652 · ClinicalTrials.gov registry record · Phase 3
A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.
A Phase 3 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 6
- Enrollment target
NCT00275652: Completed Phase 3 study, sponsored by Mayo Clinic.
NCT00275652 is a Phase 3 study that has completed, run by Mayo Clinic. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00275652, a Phase 3 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6 participants
- Enrollment target
Study Summary
This trial is being done to see if the investigational drug, LdT (Telbivudine), is safe and effective in the treatment of hepatitis B infection. In addition to this, we will be looking at the comparison of the effects (good and bad) of LdT and lamivudine.
Interventions
- DRUG LdT (Telbivudine) and lamivudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2004-06 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00275652
The ClinicalTrials.gov registry entry for NCT00275652 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LdT (Telbivudine) and lamivudine is the first listed.
NCT00275652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00275652 about?
NCT00275652 is a clinical study titled "A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.". This trial is being done to see if the investigational drug, LdT (Telbivudine), is safe and effective in the treatment of hepatitis B infection. In addition to this, we will be looking at the comparison of the effects (good and bad) of LdT and lamivudine.
What is the current status of trial NCT00275652?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 6 participants. The study started on 2004-06. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00275652?
The interventions under investigation include: LdT (Telbivudine) and lamivudine (DRUG).
Who is sponsoring clinical trial NCT00275652?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.